期刊
PHARMACEUTICS
卷 14, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics14020402
关键词
organometallics; coordination complexes; metallodrugs; fluorinated ligands; anticancer activity; cancer; cytotoxicity
资金
- PAPIIT-DGAPA-UNAM [PAPIIT IN210520, PAPIIT IT200720]
- CONACYT [A1-S-33933]
- FORDECYT-PRONACES FON.INST [FOINS 307152]
- [DMM-2016-1]
- [IT200920]
Fluorination of pharmaceutical agents is crucial for modifying their pharmacological profiles and addressing the limitations of metallodrugs, ultimately enhancing their potential anticancer activity.
Fluorination of pharmaceutical agents has afforded crucial modifications to their pharmacological profiles, leading to important advances in medicinal chemistry. On the other hand, metallodrugs are considered to be valuable candidates in the treatment of several diseases, albeit with the caveat that they may exhibit pharmacological disadvantages, such as poor water solubility, low bioavailability and short circulating time. To surmount these limitations, two approaches have been developed: one based on the design of novel metallodrug-delivering carriers and the other based on optimizing the structure of the ligands bound to the metal center. In this context, fluorination of the ligands may bring beneficial changes (physicochemical and biological) that can help to elude the aforementioned drawbacks. Thus, in this review, we discuss the use of fluorinated ligands in the design of metallodrugs that may exhibit potential anticancer activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据